Drug Evaluation in Angina Pectoris
Gianluigi Ardissino · Lionel H. Opie · Stefano Savonitto
Ara 2012 · Developments in Cardiovascular Medicine Kitap 158 · Springer Science & Business Media
E-kitap
262
Sayfa
reportPuanlar ve yorumlar doğrulanmaz Daha Fazla Bilgi
Bu e-kitap hakkında
Although there are many books on angina, few are devoted to the important problem of how to evaluate drug efficacy in angina pectoris. Drug Evaluation in Angina Pectoris has two fundamental aims: the first is to review the methodological aspects of drug evaluation in stable and unstable angina pectoris; the second is to provide a logical and methodological background for future studies aimed at assessing the ability of medical treatment to improve prognosis.
Part I updates the pathophysiology, clinical presentation and prognosis of angina pectoris. Part II aims to `put in numbers' the symptoms and signs of myocardial ischemia, starting from a revision of the currently used parameters. It is extremely important to quantify the variability of the disease for the correct design of clinical trial, a subject dealt with in Part III, which also discusses some clinico-pharmacological aspects of therapy. Part IV is a critical review of the drugs currently used for the treatment of stable and unstable angina, and particularly considers some important unresolved issues concerning their use. The current FDA and EC guidelines for the evaluation of antianginal drugs are briefly discussed in Part V, giving clinical investigators insight into how antianginal drugs are evaluated by regulatory agencies and what is considered as proof of a valid efficacy/tolerability ratio.
Drug Evaluation in Angina Pectoris will assist discerning cardiologists, pharmacologists, and advanced students of cardiology as well as innovative pharmaceutical companies, all of whom need to understand what angina is, how to evaluate treatment, and how to judge the agents used in its treatment.
Part I updates the pathophysiology, clinical presentation and prognosis of angina pectoris. Part II aims to `put in numbers' the symptoms and signs of myocardial ischemia, starting from a revision of the currently used parameters. It is extremely important to quantify the variability of the disease for the correct design of clinical trial, a subject dealt with in Part III, which also discusses some clinico-pharmacological aspects of therapy. Part IV is a critical review of the drugs currently used for the treatment of stable and unstable angina, and particularly considers some important unresolved issues concerning their use. The current FDA and EC guidelines for the evaluation of antianginal drugs are briefly discussed in Part V, giving clinical investigators insight into how antianginal drugs are evaluated by regulatory agencies and what is considered as proof of a valid efficacy/tolerability ratio.
Drug Evaluation in Angina Pectoris will assist discerning cardiologists, pharmacologists, and advanced students of cardiology as well as innovative pharmaceutical companies, all of whom need to understand what angina is, how to evaluate treatment, and how to judge the agents used in its treatment.
Bu e-kitaba puan verin
Düşüncelerinizi bizimle paylaşın.
Okuma bilgileri
Akıllı telefonlar ve tabletler
Android ve iPad/iPhone için Google Play Kitaplar uygulamasını yükleyin. Bu uygulama, hesabınızla otomatik olarak senkronize olur ve nerede olursanız olun çevrimiçi veya çevrimdışı olarak okumanıza olanak sağlar.
Dizüstü bilgisayarlar ve masaüstü bilgisayarlar
Bilgisayarınızın web tarayıcısını kullanarak Google Play'de satın alınan sesli kitapları dinleyebilirsiniz.
e-Okuyucular ve diğer cihazlar
Kobo eReader gibi e-mürekkep cihazlarında okumak için dosyayı indirip cihazınıza aktarmanız gerekir. Dosyaları desteklenen e-kitap okuyuculara aktarmak için lütfen ayrıntılı Yardım Merkezi talimatlarını uygulayın.
